Patents Examined by Nicole Kinsey White
  • Patent number: 11952401
    Abstract: The present disclosure belongs to the technical field of biological products for veterinary medicine, and specifically relates to a recombinant foot-and-mouth disease virus (FMDV) with a reduced immunosuppressive activity, a preparation method and use thereof, and a recombinant vaccine strain. According to the present disclosure, it is firstly discovered that FMDV 3B protein has an immunosuppressive function, and key sites for exerting the immunosuppressive function are found. A recombinant FMDV vaccine strain with a lost immunosuppressive function in FMDV 3B protein is constructed by introducing amino acid mutations into three repeated copies of FMDV 3B protein.
    Type: Grant
    Filed: July 14, 2021
    Date of Patent: April 9, 2024
    Assignee: Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences
    Inventors: Haixue Zheng, Fan Yang, Zixiang Zhu, Xiangle Zhang, Weijun Cao, Congcong Wang, Kangli Li, Huisheng Liu, Hong Tian, Keshan Zhang, Xiangtao Liu
  • Patent number: 11952594
    Abstract: The present invention relates to the delivery of a payload by bacterial delivery vehicle, i.e. the encapsulation and the delivery of a single plasmid by different bacterial virus particles. More specifically, the present invention concerns a pharmaceutical composition comprising a payload packaged in at least two different bacterial delivery vehicles and a method of production thereof.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: April 9, 2024
    Inventors: Antoine Decrulle, Xavier Duportet, Igor Stzepourginski
  • Patent number: 11944682
    Abstract: Aggregation-induced emission-bacteriophage bioconjugate including a bacteriophage covalently bonded to at least one aggregation-induced emission luminogen via an optional linker, pharmaceutical compositions including the same, and methods of preparation and use thereof.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: April 2, 2024
    Assignee: The Hong Kong University of Science and Technologyy
    Inventors: Benzhong Tang, Xuewen He
  • Patent number: 11926877
    Abstract: A saliva-based testing method that bypasses the need for RNA isolation/purification is described herein. In experiments with inactivated SARS-CoV-2 virus spiked into saliva, this method has a limit of detection of 500-1000 viral particles per mL, rivalling the standard NP swab method. Initial studies showed excellent performance with 100 clinical samples. This saliva-based process is operationally simple, utilizes readily available materials, and can be easily implemented by existing testing sites thus allowing for high-throughput, rapid, and repeat testing of large populations.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: March 12, 2024
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Diana Rose Ranoa, Robin L. Holland, Fadi G. Alnaji, Kelsie J. Green, Leyi Wang, Christopher B. Brooke, Martin D. Burke, Timothy M. Fan, Paul J. Hergenrother
  • Patent number: 11918639
    Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
    Type: Grant
    Filed: October 11, 2021
    Date of Patent: March 5, 2024
    Assignees: Bavarian Nordic A/S, Janssen Vaccines & Prevention B.V., The United States of America, as represented by The Secretary, Department of Health and Human Service
    Inventors: Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier, Maria Grazia Pau, Benoit Christophe Stephan Callendret, Lucy A. Ward
  • Patent number: 11918642
    Abstract: Disclosed are compositions for generating an immune response against human immunodeficiency virus (HIV) and their methods of uses.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: March 5, 2024
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Tsafrir S. Leket-Mor, Bertram Jacobs, Lydia Meador, Karen Kibler
  • Patent number: 11920149
    Abstract: The present invention relates to nucleic acid regulatory elements that are able to enhance diaphragm-specific expression of genes, in particular expression in diaphragm as such, or in combination with expression in cardiac muscle and/or skeletal muscle, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy, more particularly diaphragm-directed gene therapy, and for vaccination purposes.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: March 5, 2024
    Inventors: Lay Khim Chuah, Thierry Vandendriessche, Warut Tulalamba
  • Patent number: 11918638
    Abstract: Reported herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype in which the native positions of the NS1 and/or NS2 genes in the RSV genome are shifted to a higher position, that is at positions that are more distal to the promoter. The changes in the gene positions may be present in combination with mutations at other loci to achieve desired levels of attenuation and immunogenicity. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: March 5, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter L. Collins, Thomas Charles McCarty
  • Patent number: 11911458
    Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: February 27, 2024
    Assignee: American Gene Technologies International Inc.
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Gary Mansfield
  • Patent number: 11896633
    Abstract: Provided are engineered phages populations, which are homogeneous in length, as well as methods of making and methods of using such phages. Also provided are engineered chlorotoxin-phages as well as their methods of making and using. The disclosed homogeneous phage populations and chlorotoxin-phages may be used, for example, for treating and/or imaging tumors, such as central nervous system tumors.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: February 13, 2024
    Assignee: Massachusetts Institute of Technology
    Inventors: Angela M. Belcher, Uyanga Tsedev, Fred Lam
  • Patent number: 11898171
    Abstract: Provided is a method and composition using ROS to increase the production of bacteriophage. According to the subject matter, a production amount of bacteriophage is increased several times in the presence of the sublethal concentration of ROS for host bacteria. Therefore, the method and composition of the subject matter can be useful for producing bacteriophage, which is used as an alternative to antibiotics that cause a serious resistance problem.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: February 13, 2024
    Assignee: LYSENTECH
    Inventors: Heejoon Myung, Yunyeol Jo
  • Patent number: 11883482
    Abstract: The disclosure provides a recombinant nucleic acid of Seneca valley virus, a recombinant vaccine strain and preparation method and use thereof, and relates to the technical field of genetic engineering. The disclosure provides the recombinant nucleic acid of Seneca valley virus, recombinant Seneca valley virus comprising the recombinant nucleic acid, recombinant Seneca valley virus encoded by the recombinant nucleic acid, recombinant Seneca valley virus vaccine strain comprising the recombinant Seneca valley virus and preparation method and use thereof. According to the disclosure, a vaccine strain characterized by high antigen production capacity, remarkably reduced pathogenicity (even having no pathogenicity to pigs), strong antibody induction activity, high immune protection rate is prepared. The vaccine strain remarkably improves the biological safety and can be used for preventing and controlling Seneca valley virus in China and the neighboring countries.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: January 30, 2024
    Inventors: Haixue Zheng, Fan Yang, Zixiang Zhu, Weijun Cao, Hong Tian, Keshan Zhang, Ting Wei, Min Zheng, Wei Zhang, Wen Dang, Xusheng Ma, Dan Li, Yi Ru, Jijun He, Jianhong Guo, Xiangtao Liu
  • Patent number: 11872278
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: January 16, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Patent number: 11851672
    Abstract: The present invention provides a kit of vectors for transducing an immune cell with multiple transgenes comprising: (i) a first vector which comprises a first transgene and a nucleotide sequence encoding a transcription factor and; and (ii) a second vector which comprises a second transgene wherein expression of the second transgene within a host cell is dependent upon expression of the transcription factor.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: December 26, 2023
    Inventors: Martin Pulé, James Sillibourne, Shaun Cordoba
  • Patent number: 11850280
    Abstract: The inventive subject matter includes a viral-vectored composition made of a bacterial expression vehicle expressing one or more recombinant viral protein antigens and its method of use. In particular, this invention relates to a vaccine for oral administration. Preferably, the bacterial expression vehicle is Bacillus subtilis.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: December 26, 2023
    Assignee: US Biologic, Inc
    Inventors: Jolieke Gerdy van Oosterwijk, Andrew Raymond Peters, Douglas Steven Zatechka, Jr., Luciana Meirelles Richer, Christopher Anthony Przybyszewski
  • Patent number: 11845952
    Abstract: One disadvantage of adeno-associated virus (AAV) is low gene expression efficiency due to delayed expression of the inserted gene. Provided is a vector plasmid for producing a vector genome to be inserted into an adeno-associated virus (AAV). The vector plasmid is provided with a vector genome cassette as a template of the vector genome, and the vector genome cassette is provided with: (1) an expression cassette including a nucleic acid molecule encoding a target gene and (b) a nucleic acid molecule encoding an expression regulatory region that allows expression of the target gene; and (2) two nucleic acid molecules positioned on both sides of the expression cassette and encoding inverted terminal repeats (ITRs). Also provided is a pharmaceutical composition containing the AVV vector, for treating or preventing an eye disease or disease associated with same.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: December 19, 2023
    Inventors: Takashi Okada, Tsutomu Igarashi, Asaka Shiozawa
  • Patent number: 11840695
    Abstract: The invention relates to C. acnes strains carrying DNA vectors for the production of recombinant C. acnes phages. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a template for recombination with C. acnes phage genome leading to the insertion of a gene of interest, for the production of recombinant phages that can lead to the transgene expression into C. acnes infected by the recombinant phage. The invention encompasses, C. acnes strains containing these vectors, C. acnes recombinant phages and methods of using these recombinant phages.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: December 12, 2023
    Assignee: Eligo Bioscience
    Inventors: Aymeric Leveau, Inès Canadas Blasco, Aurélie Mathieu, Antoine Decrulle
  • Patent number: 11834722
    Abstract: A method of determining the safety and/or efficacy of a gene therapy vector prior to carrying out gene therapy on an individual includes infecting a culture of induced pluripotent stem cells obtained from the individual with a gene therapy vector. Ideally the cells are allowed to differentiate, and the infection is carried out at the start of culture and at least once during differentiation and/or after differentiation. Nucleic acids are extracted from the infected cells, and then analysed to measure and/or determine adverse effects of integration of nucleic acid from the vector and/or efficiency of expression of nucleic acid from the vector.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: December 5, 2023
    Inventor: Michael Themis
  • Patent number: 11826414
    Abstract: The present disclosure provides methods related to determining the level of afucosylated Fc glycans in IgG antibodies in a biological sample from a subject. This level can be used in methods aimed at monitoring and/or treating subject suffering from an acute flavivirus infection and/or who are at risk for progression to clinically significant infection or disease. This level can also be used in a vaccination method to ensure that those who receive a flavivirus vaccine have a reduced risk of reacting to the vaccine be developing clinically significant infection or disease. The disclosure also provides treatment methods based on inhibiting Fc?RIIA or Fc?RIIIA receptor signaling. Also provided are novel cell lines that are useful in measuring afucosylated Fc glycans.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: November 28, 2023
    Assignees: CZ Biohub SF, LLC, The Board of Trustees of the Leland Stanford Junior University
    Inventor: Taia T. Wang
  • Patent number: 11820999
    Abstract: A lentiviral vector system for expressing a lentiviral particle is disclosed. The lentiviral vector system includes a therapeutic vector. The therapeutic vector comprises a phenylalanine hydroxylase (PAH) sequence for expressing at least one of PAH or a variant thereof, wherein the PAH sequence is truncated.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: November 21, 2023
    Assignee: American Gene Technologies International Inc.
    Inventors: Tyler Lahusen, Charles David Pauza